Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-PanTumor02: Ifinatamab Deruxtecan in Recurrent or Metastatic Solid Tumors
NCT06330064Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label trial of ifinatamab deruxtecan in endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC), pancreatic ductal adenocarcinoma (PDAC) and 11 more (14 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective Response Rate, Dose-limiting Toxicities and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06330064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06330064.